NIPENT
Clinical safety rating
cautionComprehensive clinical and safety monograph for NIPENT (NIPENT).
Comprehensive clinical and safety monograph for NIPENT (NIPENT).
Hairy cell leukemiaCutaneous T-cell lymphoma
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
| Metabolism | Primarily metabolized by the liver via deamination by adenosine deaminase (ADA). |
| Excretion | Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments. |
| Protein binding | Approximately 90-95% bound to serum albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant. |
| Onset of Action | Intravenous administration: onset of clinical effect (immunosuppression) occurs within 2-4 hours after infusion. |
| Duration of Action | The immunosuppressive effect persists for 12-24 hours post-dose, with recovery of lymphocyte counts typically occurring within 24-48 hours. |
| Molecular Weight | 368.35 |
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if creatinine clearance < 60 mL/min. For ClCr 60-90 mL/min: reduce dose to 2.5 mg/m2. Not recommended if ClCr < 60 mL/min. |
| Liver impairment | No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability. |
| Pediatric use | Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing. |
| Geriatric use | No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance. |
| 1st trimester | Contraindicated due to teratogenicity in animal studies and risk of fetal harm. |
| 2nd trimester | Contraindicated; may cause fetal harm (e.g., myelosuppression). |
| 3rd trimester | Contraindicated; risk of neonatal myelosuppression and other adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for NIPENT (NIPENT).
| Placental transfer | Pentostatin crosses the placenta in animal studies; human data limited but expected to transfer. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants, including myelosuppression and immunosuppression. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction). |
| Fetal Monitoring | Complete blood counts (CBC) with differential weekly, hepatic and renal function tests, assessment for signs of infection or bleeding, fetal ultrasound for growth and anatomy if exposure occurs. |
| Fertility Effects | May cause infertility in both males and females due to gonadal suppression; oligospermia or azoospermia reported; potential for amenorrhea or premature ovarian failure. |
■ FDA Black Box Warning
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
| Serious Effects |
Hypersensitivity to pentostatinSevere renal impairment (CrCl < 60 mL/min)PregnancyBreastfeeding
| Precautions | Bone marrow suppression: monitor blood counts regularly, Renal toxicity: assess renal function before and during therapy, Hepatotoxicity: monitor liver function tests, Pulmonary toxicity: observe for signs of pneumonitis, Embryofetal toxicity: advise patients of reproductive potential to use effective contraception, Increased risk of infection: avoid live vaccines |
| Food/Dietary | Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition. No other significant food interactions are reported. |
| Clinical Pearls | Administer with aggressive pre-hydration (≥2L NS) and urine alkalinization to prevent nephrotoxicity. Monitor for severe myelosuppression, especially neutropenia. Consider leukapheresis for high-risk patients to prevent tumor lysis syndrome. Dose adjustment required for renal impairment (CrCl <60 mL/min). |
| Patient Advice | Drink at least 2-3 liters of water daily to protect kidneys. · Report any unusual bleeding, bruising, or signs of infection (fever, sore throat) immediately. · Avoid grapefruit and grapefruit juice during treatment. · Use effective contraception during and for 6 months after therapy. · Do not receive live vaccines during treatment. · Report any new or worsening shortness of breath or chest pain. |
Loading safety data…